Facebook
X
LinkedIn
ForwardPulse: Bone Up: Evaluating Evenity as Potential First Line Therapy for Osteoporosis
Evenity has both anabolic and antiresorptive properties making it an ideal medication initially for patients with osteoporosis. Despite this dual effect, it remains underutilized with preference for our oral/IV bisphosphonate agents first until patient's meet very high risk criteria to be eligible for Evenity. This presentation will increase pharmacist competency of Evenity as an osteoporosis treatment option.
Target Audience
Pharmacist
Learning Objectives
Recognize criteria for pharmacotherapy treatment of osteoporosis
Describe the advantages of Evenity in osteoporosis therapy -
Discuss Evenity being used as first line therapy in osteoporosis
Additional Information
| Attachment | Size |
|---|---|
 Disclosure + Objective Slides_Naumovski.pdf | 314.6 KB |
Evenity has both anabolic and antiresorptive properties making it an ideal medication initially for patients with osteoporosis. Despite this dual effect, it remains underutilized with preference for our oral/IV bisphosphonate agents first until patient's meet very high-risk criteria to be eligible for Evenity. This presentation will increase pharmacist competency of Evenity as an osteoporosis treatment option.
Igor Naumovski, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.